LAVAL, Quebec, Jan. 10, 2017 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX)
("Valeant" or the "Company") wholly owned subsidiary, Bausch +
Lomb, a leading global eye health company, today announced the
expanded parameter range for Bausch + Lomb ULTRA® for
Presbyopia contact lenses. Since the contact lenses first launched
in February 2016, Bausch + Lomb
ULTRA® for Presbyopia contact lenses have been available
in parameters between -7 D to +2 D. The expansion now extends the
power range available to eye care professionals and patients to
+4.50D to -10.00D (in 0.25D steps) in both low add and high
add.
Bausch + Lomb ULTRA® for Presbyopia contact lenses,
monthly replacement silicone hydrogel lenses, combine the company's
innovative MoistureSeal® technology, which delivers
exceptional end-of-day comfort1, with the proven 3-Zone
Progressive™ design also found in Biotrue® ONEday for
Presbyopia daily disposable contact lenses. The combination of
these advanced proprietary technologies provides presbyopic
patients exceptional comfort and outstanding vision at near,
intermediate, and distance.1,3
"The Bausch + Lomb ULTRA® for Presbyopia contact
lenses are providing eye care professionals a multifocal lens
option that delivers exceptional comfort and the clarity of vision
their presbyopic patients need," said Joe
Papa, Chairman and Chief Executive Officer of Valeant. "This
is just one example of our continued commitment to providing
outstanding innovations that meet the needs of our customers and
their patients."
For more information regarding the expanded parameters for the
Bausch + Lomb ULTRA® for Presbyopia contact lenses,
visit the Newsroom section at www.bausch.com
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements which
may generally be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"will," "believes," "estimates," "potential," "target," or
"continue" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties discussed in the
Company's most recent annual or quarterly report and detailed from
time to time in Valeant's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Valeant undertakes no obligation to
update any of these forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
actual outcomes, unless required by law.
References
1. Data on file. Bausch & Lomb
Incorporated. Rochester, NY;
2015.
2. Thirty-nine ECPs (from 10 countries) refitted 441 existing soft
contact lens wearing presbyopesinto PureVision®2 Presbyopia lenses.
Patients returned for follow-up.
3. Results of an online survey with habitual presbyopic contact
lens wearers who wore their lenses for approximately 5 days
(n=181). Survey questions were top 3-box scores (% Strongly Agree,
Agree, Slightly Agree) on a 6-point agreement scale.
Bausch + Lomb ULTRA, MoistureSeal, Biotrue, 3-Zone
Progressive and PureVision are trademarks of Bausch & Lomb
Incorporated.
Contact Information:
Elif McDonald
514-856-3855
877-281-6642 (toll free)
elif.mcdonald@valeant.com
Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bausch--lomb-launches-expanded-parameters-for-bausch--lomb-ultra-for-presbyopia-contact-lenses-300388286.html
SOURCE Valeant Pharmaceuticals International, Inc.